Chrousos Phaedra 4
4 · Vanda Pharmaceuticals Inc. · Filed Apr 24, 2019
Insider Transaction Report
Form 4
Chrousos Phaedra
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-04-23+35,000→ 35,000 totalExercise: $17.31Exp: 2029-04-22→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]The option vests with respect to 25% of the underlying shares when the Reporting Person completes 12 months of continuous service following the date of grant, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.